Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation

Value in Health ◽

10.1016/j.jval.2015.09.1085 ◽

2015 ◽

Vol 18 (7) ◽

pp. A441-A442

Author(s):

A Kulikov ◽

R Yagudina ◽

MV Protsenko

Keyword(s):

Chronic Myelogenous Leukemia ◽

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Myelogenous Leukemia ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

The Russian Federation

Download Full-text

PCN90 - COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF NILOTINIB FOR THE SECOND LINE TRATMENT OF CHRONIC MIELOID LEUKEMIA IN THE RUSSIAN FEDERATION

Value in Health ◽

10.1016/j.jval.2018.09.172 ◽

2018 ◽

Vol 21 ◽

pp. S29

Author(s):

N.A. Avxentyev ◽

M.Y. Frolov ◽

A.S. Makarov

Keyword(s):

Cost Effectiveness ◽

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Second Line ◽

The Russian Federation

Download Full-text

Budget Impact Analysis on the intranasal form of Interferon-Gamma in the Complex Therapy of Influenza in the Russian Federation

International Journal of Pharmaceutical Research ◽

10.31838/ijpr/2018.10.04.053 ◽

2021 ◽

Vol 10 (04) ◽

Keyword(s):

Interferon Gamma ◽

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Complex Therapy ◽

The Russian Federation

Download Full-text

Budget Impact Analysis Of Formoterol Easyhaler In The Treatment Of Asthma In Children In The Russian Federation

Value in Health ◽

10.1016/j.jval.2015.09.1396 ◽

2015 ◽

Vol 18 (7) ◽

pp. A497

Author(s):

A Kulikov ◽

E Kilimanova

Keyword(s):

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

The Russian Federation ◽

Asthma In Children

Download Full-text

Incidence of hyperlipidemia among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e18108 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e18108-e18108 ◽

Author(s):

Meg Franklin ◽

Leah Burns ◽

Samuel Perez ◽

Deepak Yerragolam ◽

Dinara Makenbaeva

Keyword(s):

Chronic Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

Incidence of type II diabetes mellitus among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e18126 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e18126-e18126 ◽

Author(s):

Meg Franklin ◽

Leah Burns ◽

Samuel Perez ◽

Deepak Yerragolam ◽

Dinara Makenbaeva

Keyword(s):

Diabetes Mellitus ◽

Chronic Myelogenous Leukemia ◽

Type Ii Diabetes ◽

Type Ii Diabetes Mellitus ◽

Myelogenous Leukemia ◽

Type Ii ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

BUDGET IMPACT ANALYSIS OF SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS IN THE RUSSIAN FEDERATION

Pharmacoeconomics theory and practice ◽

10.30809/phe.2.2020.3 ◽

2020 ◽

Vol 8 (2) ◽

pp. 23-28

Author(s):

V.G Serpik ◽

A.Yu Kulikov ◽

T.V Dubinina ◽

M.V Protsenko

Keyword(s):

Ankylosing Spondylitis ◽

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

The Russian Federation

Download Full-text

Combinations of Interferon-α with Other Cytokines as Initial and Second-Line Therapy of Chronic Myelogenous Leukemia

Contributions to Oncology - Cytokines in Cancer Therapy ◽

10.1159/000422805 ◽

1994 ◽

pp. 24-29

Author(s):

Otto Kloke

Keyword(s):

Chronic Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Interferon Α ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

Use of PD-L1 Biomarker in Second Line Therapy for Non-Small Cell Lung Cancer: Budget Impact Analysis from a Private Payer Perspective In Brazil

Value in Health ◽

10.1016/j.jval.2018.04.138 ◽

2018 ◽

Vol 21 ◽

pp. S23 ◽

Author(s):

L Chabrol Haas ◽

MB Coutinho ◽

RB Peixoto ◽

AS Ranieri ◽

FB Serra

Keyword(s):

Lung Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy ◽

Payer Perspective ◽

Download Full-text

PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION

Value in Health ◽

10.1016/j.jval.2019.09.2370 ◽

2019 ◽

Vol 22 ◽

pp. S848

Author(s):

R. Yagudina ◽

A. Kulikov ◽

V. Serpik ◽

E. Kostina

Keyword(s):

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Mucopolysaccharidosis Type ◽

Type Ii ◽

Mucopolysaccharidosis Type Ii ◽

The Russian Federation

Download Full-text

Validation of the “budget impact analysis” model of the introduction of dolutegravir drug into the public procurement of antiretroviral drugs in the Russian Federation

Pharmacoeconomics theory and practice ◽

10.30809/phe.3.2017.2 ◽

2017 ◽

Vol 5 (3) ◽

pp. 64-66

Author(s):

V.V. Babiy ◽

A.Yu. Kulikov

Keyword(s):

Russian Federation ◽

Impact Analysis ◽

Budget Impact ◽

Public Procurement ◽

Antiretroviral Drugs ◽

Budget Impact Analysis ◽

Analysis Model ◽

The Russian Federation

Download Full-text